LPRI-CF113
Product
Exeltis, USA Inc.
Total Payments
$11.6M
Transactions
907
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $11.1M | 790 | 0 |
| 2022 | $457,388 | 117 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.6M | 907 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women | Exeltis, USA Inc. | $11.1M | 0 |
| Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females | Exeltis, USA Inc. | $457,388 | 0 |
Top Doctors Receiving Payments for LPRI-CF113
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Columbus, OH | $11.6M | 907 |
Ad
Manufacturing Companies
- Exeltis, USA Inc. $11.6M
Product Information
- Type Product
- Total Payments $11.6M
- Total Doctors 0
- Transactions 907
About LPRI-CF113
LPRI-CF113 is a product associated with $11.6M in payments to 0 healthcare providers, recorded across 907 transactions in the CMS Open Payments database. The primary manufacturer is Exeltis, USA Inc..
Payment data is available from 2022 to 2023. In 2023, $11.1M was paid across 790 transactions to 0 doctors.
The most common payment nature for LPRI-CF113 is "Unspecified" ($11.6M, 100.0% of total).
LPRI-CF113 is associated with 2 research studies, including "LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women" ($11.1M).